Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hemophilia (Jan 2017)

Posted by Matt Breese on Jan 9, 2017

Find me on:

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for hemophilia treatments shows that health exchange formularies are the most restrictive on average. This analysis also shows that prior authorizations are much more common than step edits. 



Trends: One trend is the expanded role of Hemophilia brand marketers to focus more on consumer marketing over traditional physician marketing. Recent data shows that a massive percentage of Hemophilia patients are making their own treatment decisions.

To read the full Reality Check on Hemophilia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check



Topics: Specialty, Market Access, Payer, Branding & Marketing